<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471015</url>
  </required_header>
  <id_info>
    <org_study_id>49096</org_study_id>
    <nct_id>NCT01471015</nct_id>
  </id_info>
  <brief_title>Darbe Administration in Newborns Undergoing Cooling for Encephalopathy</brief_title>
  <acronym>DANCE</acronym>
  <official_title>Darbe Administration in Newborns Undergoing Cooling for Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Selective head cooling or whole body hypothermia has become the standard of care for neonatal
      hypoxia-ischemia encephalopathy (HIE). Despite early intervention death or major
      neurodevelopmental disability still occurs in nearly 50% of infants ≥ 36 weeks gestational
      age (GA) treated with cooling. No additional therapies have proven to be efficacious in
      further reducing brain injury and impairment for these high risk infants. Neuroprotective
      strategies aimed at improving early childhood outcomes are still needed. An important area of
      study includes therapies that may complement the neuroprotective effects of hypothermia and
      promote neuronal regeneration, recovery and neurovascular remodeling. Among these therapies,
      erythropoiesis stimulating agents (ESA) have been shown to provide neuroprotection, improving
      short and long-term neurologic outcome in brain injury and HIE in neonatal and adult animal
      models. Parallel with neuroprotective effects in experimental settings, recent small clinical
      studies suggest improved outcomes after ESA administration in patients with severe traumatic
      brain injury and HIE. ESA may work through several important mechanisms including reduced
      inflammation, limited oxidative stress, decreased apoptosis and white matter injury, as well
      as via pro-angiogenic and neurogenic properties.

      Darbepoetin alfa (Darbe), a recombinant human erythropoietin (EPO)-derived molecule, has an
      extended circulating half life and comparable biological activity to EPO, including
      activation of the EPO receptor. The proposed study is a Phase I/II dose safety and
      pharmacokinetic trial of early Darbe administered concurrent with hypothermia in human
      newborn infants with moderate to severe birth asphyxia. The long-term objectives of the
      proposed research are to reduce mortality and to decrease the risk of long-term disabilities
      in infants with HIE who survive beyond the newborn period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Pharmacokinetic Profile of Darbe After the First Dose During Cooling</measure>
    <time_frame>For 72 hours after first dose</time_frame>
    <description>The pharmacokinetic profile of Darbe wil be determined using &quot;population&quot; pharmacokinetic sampling in which babies will be randomized to have blood drawn at different intervals. Serum levels will be drawn at 4,12, 18, 24, 36, 60, and 72 hours post initial dose. Area under the plasma concentration versus time curve (AUC) will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Pharmacokinetic Profile of Darbe After the Second Dose.</measure>
    <time_frame>For 36 hours after second dose</time_frame>
    <description>The pharmacokinetic profile of Darbe will be determined using &quot;population&quot; pharmacokinetic sampling in which babies will be randomized to have blood drawn at different intervals. A second dose of Darbe will be given at 7 days of age, and serum drug levels will be obtained at 12, 18, 24, and 36 hours post second dose. Area under the plasma concentration versus time curve (AUC) will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events.</measure>
    <time_frame>30 days or until hospital discharge</time_frame>
    <description>Potential adverse events such as (but not limited to) alterations in blood pressure, secondary infections, neutropenia, thrombotic/vascular events, hematologic events (platelets, Hct level, polycythemia), and hepatic/renal function that are outside of normal range for the study population.
Complications associated with HIE or cooling therapy will not be considered an AE for this study. AEs reported to be associated with cooling include: bleeding/thrombosis, persistent pulmonary hypertension of the newborn (PPHN), skin changes, arrhythmia, and persistent acidosis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypoxic Ischemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>High dose Darbepoetin alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose Darbepoetin alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.</description>
    <arm_group_label>High dose Darbepoetin alfa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.</description>
    <arm_group_label>Low dose Darbepoetin alfa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Infants will be eligible for the DANCE trial if they have a gestational age &gt; 36 weeks by
        best obstetric estimate, are &lt; 12 hours old and have evidence of moderate-severe acute
        perinatal HIE. Eligibility will also include criteria presently used in the NICU to
        initiate hypothermia:

          1. &lt; 6 hours after birth

          2. History of an acute perinatal event (abruption, cord prolapsed, severe fetal heart
             rate abnormality)

          3. Severe fetal or early (&lt; 1 hour age) neonatal acidosis: arterial pH ≤ 7.0 or a base
             deficit ≥ 16m mEq/ L

          4. If a blood gas is not available or a blood gas at &lt;1 hour of age has a pH between 7.01
             and 7.15, or a base deficit is between 10 and 15.9 mEq/L, additional criteria will be
             required:

               -  acute perinatal event AND

               -  either a 10-min Apgar score ≤ 5 or assisted ventilation initiated at birth and
                  continued for at least 10 minutes.

        Exclusion Criteria:

          1. Major congenital and/or chromosomal abnormalities

          2. Prenatal diagnosis of brain abnormality or hydrocephalus

          3. Severe growth restriction (&lt; 1800g)

          4. Central venous hematocrit &gt; 65%, platelet count &gt; 600,000/dL, and/or neutropenia (ANC
             &lt; 500 µL)

          5. Maternal history of major vascular thrombosis or multiple fetal losses (&gt; 3
             spontaneous abortions)

          6. ECMO

          7. Infant judged critically ill and unlikely to benefit from neonatal intensive care by
             the attending neonatologist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariana Baserga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-9544</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKay Dee Hospital- Intermountain Healthcare</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>841074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <results_first_submitted>May 6, 2015</results_first_submitted>
  <results_first_submitted_qc>May 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2015</results_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Mariana Baserga</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypoxic Ischemic Encephalopathy</keyword>
  <keyword>Cooling Therapy</keyword>
  <keyword>HIE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose Darbepoetin Alfa</title>
          <description>10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
Darbepoetin alfa: 10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Darbepoetin Alfa</title>
          <description>2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
Darbepoetin alfa: 2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old
Placebo: Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Darbepoetin Alfa</title>
          <description>10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
Darbepoetin alfa: 10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Darbepoetin Alfa</title>
          <description>2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
Darbepoetin alfa: 2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old
Placebo: Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="B2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="B3" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="B4" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events.</title>
        <description>Potential adverse events such as (but not limited to) alterations in blood pressure, secondary infections, neutropenia, thrombotic/vascular events, hematologic events (platelets, Hct level, polycythemia), and hepatic/renal function that are outside of normal range for the study population.
Complications associated with HIE or cooling therapy will not be considered an AE for this study. AEs reported to be associated with cooling include: bleeding/thrombosis, persistent pulmonary hypertension of the newborn (PPHN), skin changes, arrhythmia, and persistent acidosis.</description>
        <time_frame>30 days or until hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Darbepoetin Alfa</title>
            <description>10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
Darbepoetin alfa: 10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Darbepoetin Alfa</title>
            <description>2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
Darbepoetin alfa: 2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old
Placebo: Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events.</title>
          <description>Potential adverse events such as (but not limited to) alterations in blood pressure, secondary infections, neutropenia, thrombotic/vascular events, hematologic events (platelets, Hct level, polycythemia), and hepatic/renal function that are outside of normal range for the study population.
Complications associated with HIE or cooling therapy will not be considered an AE for this study. AEs reported to be associated with cooling include: bleeding/thrombosis, persistent pulmonary hypertension of the newborn (PPHN), skin changes, arrhythmia, and persistent acidosis.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Pharmacokinetic Profile of Darbe After the First Dose During Cooling</title>
        <description>The pharmacokinetic profile of Darbe wil be determined using &quot;population&quot; pharmacokinetic sampling in which babies will be randomized to have blood drawn at different intervals. Serum levels will be drawn at 4,12, 18, 24, 36, 60, and 72 hours post initial dose. Area under the plasma concentration versus time curve (AUC) will be used.</description>
        <time_frame>For 72 hours after first dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Darbepoetin Alfa</title>
            <description>10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
Darbepoetin alfa: 10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Darbepoetin Alfa</title>
            <description>2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
Darbepoetin alfa: 2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetic Profile of Darbe After the First Dose During Cooling</title>
          <description>The pharmacokinetic profile of Darbe wil be determined using &quot;population&quot; pharmacokinetic sampling in which babies will be randomized to have blood drawn at different intervals. Serum levels will be drawn at 4,12, 18, 24, 36, 60, and 72 hours post initial dose. Area under the plasma concentration versus time curve (AUC) will be used.</description>
          <units>AUC (h*mU/L)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180,866" lower_limit="146,568" upper_limit="199,680"/>
                    <measurement group_id="O2" value="26,555" lower_limit="20,049" upper_limit="35,029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Pharmacokinetic Profile of Darbe After the Second Dose.</title>
        <description>The pharmacokinetic profile of Darbe will be determined using &quot;population&quot; pharmacokinetic sampling in which babies will be randomized to have blood drawn at different intervals. A second dose of Darbe will be given at 7 days of age, and serum drug levels will be obtained at 12, 18, 24, and 36 hours post second dose. Area under the plasma concentration versus time curve (AUC) will be used.</description>
        <time_frame>For 36 hours after second dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Darbepoetin Alfa</title>
            <description>10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
Darbepoetin alfa: 10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Darbepoetin Alfa</title>
            <description>2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
Darbepoetin alfa: 2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetic Profile of Darbe After the Second Dose.</title>
          <description>The pharmacokinetic profile of Darbe will be determined using &quot;population&quot; pharmacokinetic sampling in which babies will be randomized to have blood drawn at different intervals. A second dose of Darbe will be given at 7 days of age, and serum drug levels will be obtained at 12, 18, 24, and 36 hours post second dose. Area under the plasma concentration versus time curve (AUC) will be used.</description>
          <units>AUC (h*mU/L)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56233" lower_limit="54915" upper_limit="71260"/>
                    <measurement group_id="O2" value="10790" lower_limit="7043" upper_limit="13493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High Dose Darbepoetin Alfa</title>
          <description>10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
Darbepoetin alfa: 10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Darbepoetin Alfa</title>
          <description>2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
Darbepoetin alfa: 2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old
Placebo: Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Multi-organ failure due to Hypoxic-Ischemic Encephalopothy</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Defined as systolic blood pressure &lt;/= to 50 mmHg requiring inotrope support</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Hepatic Function</sub_title>
                <description>Defined as aspartate aminotransferase (AST) &gt;200 IU/L or alanine aminotransferase (ALT) &gt;100 IU/L</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizures</sub_title>
                <description>New onset seizures that appeared after the first dose of study drug</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Renal Function</sub_title>
                <description>Defined as urine output &lt;0.5 mL/k/h for &gt;24 hours or serum creatinine &gt;1.5 mg/dL</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the small number of participants, infrequent adverse events may not have been detected. There is a lack of long-term follow up to assess for long-term safety concerns.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mariana Baserga</name_or_title>
      <organization>University of Utah</organization>
      <phone>801-581-7052</phone>
      <email>mariana.baserga@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

